Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JIN-A04
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : J Ints Bio
Deal Size : $325 million
Deal Type : Licensing Agreement
Details : The license agreement is for JIN-A04, an oral Tyrosine Kinase Inhibitor (TKI) targeting non-small cell lung cancer carrying HER2 mutations. There is currently no oral drug approved to date.
Product Name : JIN-A04
Product Type : Undisclosed
Upfront Cash : $1.9 million
May 31, 2023
Lead Product(s) : JIN-A04
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : J Ints Bio
Deal Size : $325 million
Deal Type : Licensing Agreement
Lead Product(s) : Lazertinib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Yuhan’s Lung Cancer Treatment Lazertinib Wins Approval
Details : The Ministry of Food and Drug Safety announced its approval for the third-generation non-small cell lung cancer treatment, Leclaza. Leclaza is a swallowable tablet that can be taken at a fixed time every day, regardless of meals.
Product Name : Leclaza
Product Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2021
Lead Product(s) : Lazertinib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
